This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Illumina (ILMN) Q3 Earnings Beat Estimates, '22 View Slashed
by Zacks Equity Research
Delays in instruments and consumables purchases, negative foreign exchange impact and consumables inventory deleveraging are expected to impede growth in the rest of 2022 for Illumina (ILMN).
Allscripts (MDRX) Q3 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Allscripts' (MDRX) robust Q3 results demonstrate strength in both segments.
AMN Healthcare (AMN) Q3 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
AMN Healthcare's (AMN) robust Q3 results demonstrate its segmental strength.
Accuray's (ARAY) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Despite solid product demand, Accuray (ARAY) reports an overall soft Q1 performance.
Myriad Genetics (MYGN) Q3 Earnings Miss, Gross Margin Falls
by Zacks Equity Research
Myriad Genetics (MYGN) hereditary cancer testing volume returns to growth in the third quarter. GeneSight comes up with yet another strong performance.
AmerisourceBergen (ABC) Q4 Earnings & Revenues Top Estimates
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal fourth-quarter 2022 results benefit from segmental growth.
LHC Group's (LHCG) Q3 Earnings & Revenues Miss Estimates
by Zacks Equity Research
LHC Group's (LHCG) third-quarter results benefit from organic growth in hospice admissions. However, home health admissions decline organically.
Chemed (CHE) Q3 Earnings Surpass Estimates, EPS View Up
by Zacks Equity Research
Chemed's (CHE) full-year VITAS revenues, prior to Medicare Cap, are once again estimated to decline.
Inari Medical (NARI) Q3 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Inari Medical's (NARI) third-quarter results benefit from significant progress made across all its growth drivers.
Inogen (INGN) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Inogen's (INGN) third-quarter results benefit from higher revenues in its domestic business-to-business sales channel.
Glaukos (GKOS) Beats on Q3 Earnings, Tightens Sales View
by Zacks Equity Research
Glaukos' (GKOS) Q3 revenues fall year over year but beat estimates. Lower revenues along with higher expenses hurt margins.
Nevro (NVRO) Q3 Earnings Beat Estimates, 2022 View Revised
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues improved on a year-over-year basis in Q3, partly owing to robust domestic performance.
QuidelOrtho (QDEL) Q3 Earnings Top Estimates, 2022 View Revised
by Zacks Equity Research
QuidelOrtho's (QDEL) robust results in POC and Donor Screening product lines drives its third-quarter 2022 top line.
Charles River (CRL) Q3 Earnings Top Estimates, Margins Dip
by Zacks Equity Research
Headwinds associated with foreign exchange due to the strengthening of the U.S. dollar and interest expense due to a rising interest rate environment increase concerns for Charles River (CRL).
Zimmer Biomet (ZBH) Q3 Earnings Beat, Gross Margin Falls
by Zacks Equity Research
Each of Zimmer Biomet's (ZBH) geographic segments and product divisions barring S.E.T. and "Other" record year-over-year sales growth at CER.
CVS Health (CVS) Q3 Earnings Surpass Estimates, View Up
by Zacks Equity Research
Robust sales growth across all three operating segments drive CVS Health's (CVS) top line.
Hologic (HOLX) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Lower sales of COVID-19 assays and supply chain challenges drag Hologic's (HOLX) top line down.
Fresenius Medical's (FMS) Q3 Earnings and Revenues Top
by Zacks Equity Research
Fresenius Medical's (FMS) third-quarter revenues benefit from strong performance across all the geographic regions and segments. However, rising costs hurt margins.
McKesson (MCK) Q2 Earnings Miss Estimates, Revenues Rise Y/Y
by Zacks Equity Research
McKesson's (MCK) fiscal second-quarter 2023 results benefit from segmental growth.
Catalent (CTLT) Q1 Earnings Lag Estimates, FY23 View Cut
by Zacks Equity Research
Catalent (CTLT) records robust first-quarter fiscal 2023 results of its Pharma and Consumer Health segment despite overall soft performance.
IDEXX (IDXX) Q3 Earnings Beat Estimates, 2022 EPS View Down
by Zacks Equity Research
IDEXX's (IDXX) Q3 top-line performance rides on strong CAG Diagnostics recurring revenue growth.
Stryker's (SYK) Q3 Earnings Miss Estimates, Volume Improves
by Zacks Equity Research
Stryker's (SYK) third-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurt sales growth.
Ecolab (ECL) Q3 Earnings & Revenues Miss Mark, Margins Down
by Zacks Equity Research
Ecolab's (ECL) robust performance across all its segments drives its Q3 sales, despite business challenges.
Henry Schein (HSIC) Q3 Earnings In Line, 2022 Sales View Down
by Zacks Equity Research
Severe currency headwinds and lower sales of PPE and COVID-19 test kits affect Henry Schein's (HSIC) top line in Q3.
Teleflex (TFX) Q3 Earnings Top Estimates, Adjusted EPS View Cut
by Zacks Equity Research
For UroLift, Teleflex (TFX) currently assumes 2022 revenues to be roughly $320 million, down from the prior guidance of $335 million.